The research and development of bispecific antibodies

A bispecific antibody (BsAb) is a kind of engineered antibody that targets two or more different epitopes simultaneously on the same or different antigens, with merits which cannot be achieved by the conventional monospecific antibody. Until now, three BsAb drugs (Catumaxomab, Blinatumomab and Emicizumab) have been approved by FDA and more than 110 BsAb drugs are being developed around the world. This review focuses on the advances in BsAb development, the BsAb platforms, and their current and potential clinical applications.